神経内分泌腫瘍におけるソマトスタチン受容体シンチグラフィと病理組織との対比についての検討

Comparative study of somatostatin receptor scintigraphy and pathological findings about neuro endocrine tumors（NETs）

20年前より欧米で使用されていた，¹¹¹Inペンテトレオチドを用いたソマトスタチン受容体シンチグラフィ（somatostatin receptor scintigraphy：SRS）は，2016年1月より我が国の実臨床での運用が開始された。これまでの海外のデータをもとに，我が国における神経内分泌腫瘍（neuroendocrine tumor：NET）診療の様々な場面で，様々な用途での使用が検討されている。

The purpose of this study was to evaluate the clinical efficacy of ¹¹¹In-pentetreotide somatostatin receptor scintigraphy（SRS）for detect of the lesion area in patients with neuroendocrine tumors（NETs）. We compared the pathological findings of NETs with SRS. Forty one patients（18 males, 23 females, mean age 59 years, range 29-86）with NETs were retrospectively enrolled in this study. Primary sites were located in pancreas（n＝26）, stomach（n＝1）, small intestine（n＝4）, colon（n＝6）, other lesion（n＝2）, and unknown（n＝2）. According to WHO 2010 classification, Grad 1（G1）was seven cases, Grade 2（G2）was thirty one cases, and Grade 3（G3）was three cases. SRS showed positive findings in 6（86％）G1 cases, 29（94％）G2 cases, and 1（33％）G3 case. In 27 of 29 cases（93.1％）, there was concordance of SSTR2a expression with SRS findings. The results of our study suggested that SRS could detect almost of all G1 and G2 NETs. SRS findings were high concordant with pathological findings.